In restrictive cardiomyopathy, the heart is of normal size or only slightly enlarged. However, it cannot relax normally during the time between heartbeats when the blood returns from the body (diastole).
Later in the disease, the heart may not pump blood strongly. The abnormal heart function can affect the lungs, liver, and other body systems. Restrictive cardiomyopathy may affect either or both ventricles. It is usually associated with a disease of the heart muscle.
Although restrictive cardiomyopathy is a rare condition, the most common causes are amyloidosis and scarring of the heart from an unknown cause (idiopathic myocardial fibrosis). It can occur after a heart transplant.
Other causes of restrictive cardiomyopathy include:
When the cause of any cardiomyopathy can be found, that condition is treated.
Few treatments are known to be effective for restrictive cardiomyopathy. The main goal of treatment is to control symptoms and improve quality of life.
The following treatments may be used to control symptoms or prevent problems:
Blood thinning medications, either aspirin or warfarin
Chemotherapy (in some situations)
Diuretics to remove fluid and help improve breathing
Medications to prevent or control uneven or abnormal heart rhythms
Steroids for some causes
A heart transplant may be considered if the heart function is very poor and the patient has severe symptoms.
People with this condition often develop heart failure that gets worse. Problems with "leaky" heart valves may also occur.
People with restrictive cardiomyopathy may be heart transplant candidates. The outlook depends on the cause of the condition, but it is usually poor. Average survival after diagnosis is 9 years.
Calling your health care provider
Call your health care provider if you have symptoms of restrictive cardiomyopathy.
Hare JM. The dilated, restrictive, and infiltrative cardiomyopathies. In: Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2011:chap 68.
Michael A. Chen, MD, PhD, Assistant Professor of Medicine, Division of Cardiology, Harborview Medical Center, University of Washington Medical School, Seattle, Washington. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M. Health Solutions, Ebix, Inc.